Aligos Therapeutics (NASDAQ:ALGS) Announces Earnings Results, Misses Estimates By $0.92 EPS

Aligos Therapeutics (NASDAQ:ALGS) issued its earnings results on Wednesday. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92), Zacks reports. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. During the same quarter in the previous year, the firm posted ($10.25) earnings per share.

Aligos Therapeutics Price Performance

Shares of NASDAQ:ALGS traded up $0.27 during midday trading on Friday, hitting $10.19. 108,249 shares of the company’s stock were exchanged, compared to its average volume of 39,795. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $30.00. The company has a market cap of $32.61 million, a PE ratio of -0.50 and a beta of 2.11. The stock has a 50 day moving average price of $9.81 and a 200-day moving average price of $12.63.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a report on Thursday.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).